Cited by 152Genetic Associations and EpidemiologyLipoproteins and Cardiovascular HealthNutrition, Genetics, and Disease

Clinical utility of polygenic risk scores for coronary artery disease

Open access
Klarin, Derek, Natarajan, Pradeep·2022·Nature Reviews Cardiology

Abstract

Over the past decade, substantial progress has been made in the discovery of alleles contributing to the risk of coronary artery disease. In addition to providing causal insights into disease, these endeavours have yielded and enabled the refinement of polygenic risk scores. These scores can be used to predict incident coronary artery disease in multiple cohorts and indicate the clinical response to some preventive therapies in post hoc analyses of clinical trials. These observations and the widespread ability to calculate polygenic risk scores from direct-to-consumer and health-care-associated biobanks have raised many questions about responsible clinical adoption. In this Review, we describe technical and downstream considerations for the derivation and validation of polygenic risk scores and current evidence for their efficacy and safety. We discuss the implementation of these scores in clinical medicine for uses including risk prediction and screening algorithms for coronary artery disease, prioritization of patient subgroups that are likely to derive benefit from treatment, and efficient prospective clinical trial designs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-021-00638-w

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Digital clinical trials could leverage multiple sources of participants' data to enable automatic phenotyping and subgrouping, which could be useful for adaptive clinical trial designs that use ongoing results to modify the trial in real time.

    “Digital clinical trials could leverage multiple sources of participants' data to enable automatic phenotyping and subgrouping 34 , which could be useful for adaptive clinical trial designs that use ongoing results to modify the trial in real time 39,40 .”

    From Multimodal biomedical AI (2022) · cites this paper as [40]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [84]Muse ED Response to polygenic risk: results of the MyGeneRank Mobile Application-Based Coronary Artery Disease Study. Preprint at MedRxiv 10.1101/2021.04.26.21256141 (2021). · DOI

Cited by

Sorted by citations

Authors
Klarin, D., & Natarajan, P.
Affiliations
Broad Institute (US)
Corresponding author
Natarajan, Pradeep
Venue
Nature Reviews Cardiology
Published
2021-11-22
Volume
19
Issue
5
Pages
291-301
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W3216708429
Cited by
152
References
143
Citations by year
2026: 29 · 2025: 37 · 2024: 38 · 2023: 33 · 2022: 15
FWCI
3.20
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R01HL127564)
  • National Human Genome Research Institute (U01HG011719)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Keywords
polygenic risk score, coronary artery disease, clinical implementation, risk prediction, screening algorithm, clinical trial design, risk score validation
MeSH terms
Coronary Artery Disease, Humans, Prospective Studies, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review